Which has higher valuation & earnings, ELVN or SANA?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is ELVN or SANA more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Sana Biotechnology N/A -103.02% -39.16%

Does the media prefer ELVN or SANA?

In the previous week, Enliven Therapeutics had 9 more articles in the media than Sana Biotechnology. MarketBeat recorded 11 mentions for Enliven Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.55 beat Enliven Therapeutics' score of 0.28 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or SANA?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Sana Biotechnology. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat ACADIA Pharmaceuticals' score of 0.01 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDYA or SANA?

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 2 mentions for Sana Biotechnology. IDEAYA Biosciences' average media sentiment score of 0.82 beat Sana Biotechnology's score of 0.55 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or SANA more profitable?

Denali Therapeutics' return on equity of -55.27% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to DNLI or SANA?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Sana Biotechnology's average media sentiment score of 0.55 beat Denali Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SANA or RCUS?

In the previous week, Arcus Biosciences had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Arcus Biosciences and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat Arcus Biosciences' score of -0.16 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Sana Biotechnology (SANA) Competitors

$2.79 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.78 -0.01 (-0.32%)

As of 10/9/2026 07:55 PM Eastern

Compare

SANA vs. ELVN, ACAD, IDYA, DNLI, and RCUS

Should you buy Sana Biotechnology stock or one of its competitors? Sana Biotechnology's main competitors and comparable companies include Enliven Therapeutics (ELVN), ACADIA Pharmaceuticals (ACAD), IDEAYA Biosciences (IDYA), Denali Therapeutics (DNLI), and Arcus Biosciences (RCUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sana Biotechnology compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Sana Biotechnology	N/A	-103.02%	-39.16%

Enliven Therapeutics currently has a consensus target price of $74.44, suggesting a potential upside of 81.66%. Sana Biotechnology has a consensus target price of $9.33, suggesting a potential upside of 234.53%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

In the previous week, Enliven Therapeutics had 9 more articles in the media than Sana Biotechnology. MarketBeat recorded 11 mentions for Enliven Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.55 beat Enliven Therapeutics' score of 0.28 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enliven Therapeutics and Sana Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

ACADIA Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Sana Biotechnology's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Sana Biotechnology	N/A	-103.02%	-39.16%

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Sana Biotechnology. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat ACADIA Pharmaceuticals' score of 0.01 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals presently has a consensus price target of $32.71, suggesting a potential upside of 65.37%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 234.53%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

ACADIA Pharmaceuticals beats Sana Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 2 mentions for Sana Biotechnology. IDEAYA Biosciences' average media sentiment score of 0.82 beat Sana Biotechnology's score of 0.55 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Sana Biotechnology	N/A	-103.02%	-39.16%

IDEAYA Biosciences has higher revenue and earnings than Sana Biotechnology. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences presently has a consensus price target of $52.69, indicating a potential upside of 45.92%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 234.53%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Summary

IDEAYA Biosciences beats Sana Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 84.30%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 234.53%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Sana Biotechnology's average media sentiment score of 0.55 beat Denali Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Sana Biotechnology has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.41	-$512.54M	-$2.84	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Denali Therapeutics' return on equity of -55.27% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Sana Biotechnology beats Denali Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Arcus Biosciences?

Sana Biotechnology (NASDAQ:SANA) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Sana Biotechnology has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Arcus Biosciences	$247M	12.56	-$353M	-$3.90	N/A

Sana Biotechnology presently has a consensus price target of $9.33, indicating a potential upside of 234.53%. Arcus Biosciences has a consensus price target of $38.30, indicating a potential upside of 57.13%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sana Biotechnology is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Sana Biotechnology has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arcus Biosciences had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Arcus Biosciences and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat Arcus Biosciences' score of -0.16 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Sana Biotechnology has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

Sana Biotechnology beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$835.22M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-3.67	13.62	275.30	26.16
Price / Sales	N/A	1,234.33	635.97	107.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	4.65	17.17	11.22	6.33
Net Income	-$244.17M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-3.46%	-1.34%	-0.89%	-1.40%
1 Month Performance	-9.71%	-8.45%	-4.42%	-3.47%
1 Year Performance	-35.42%	14.02%	7.03%	1.18%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	3.5262 of 5 stars	$2.79 flat	$9.33 +234.5%	-37.3%	$835.22M	N/A	N/A	142	Positive News
ELVN Enliven Therapeutics	2.7913 of 5 stars	$45.47 -3.2%	$74.44 +63.7%	+92.5%	$3.44B	N/A	N/A	67	Positive News Analyst Forecast
ACAD ACADIA Pharmaceuticals	4.7258 of 5 stars	$20.11 +0.8%	$32.76 +62.9%	-4.1%	$3.44B	$1.14B	9.06	798	Analyst Forecast
IDYA IDEAYA Biosciences	3.8877 of 5 stars	$38.06 +1.9%	$52.69 +38.4%	+34.8%	$3.28B	$234.13M	N/A	145	News Coverage Insider Trade
DNLI Denali Therapeutics	3.4829 of 5 stars	$19.91 -0.5%	$35.85 +80.0%	+20.3%	$3.20B	$3.60M	N/A	507	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. ELVN, ACAD, IDYA, DNLI, and RCUS

How does Sana Biotechnology compare to Enliven Therapeutics?

Summary

How does Sana Biotechnology compare to ACADIA Pharmaceuticals?

Summary

How does Sana Biotechnology compare to IDEAYA Biosciences?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Summary

How does Sana Biotechnology compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. ELVN, ACAD, IDYA, DNLI, and RCUS

How does Sana Biotechnology compare to Enliven Therapeutics?

Do insiders and institutionals hold more shares of ELVN or SANA?

Is ELVN or SANA more profitable?

Do analysts recommend ELVN or SANA?

Which has higher valuation & earnings, ELVN or SANA?

Which has more volatility & risk, ELVN or SANA?

Does the media prefer ELVN or SANA?

Summary

How does Sana Biotechnology compare to ACADIA Pharmaceuticals?

Which has more risk & volatility, ACAD or SANA?

Is ACAD or SANA more profitable?

Does the media favor ACAD or SANA?

Which has better earnings and valuation, ACAD or SANA?

Do insiders and institutionals have more ownership in ACAD or SANA?

Do analysts prefer ACAD or SANA?

Summary

How does Sana Biotechnology compare to IDEAYA Biosciences?

Does the media refer more to IDYA or SANA?

Is IDYA or SANA more profitable?

Which has higher valuation & earnings, IDYA or SANA?

Do institutionals & insiders believe in IDYA or SANA?

Do analysts rate IDYA or SANA?

Which has more risk & volatility, IDYA or SANA?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Do institutionals & insiders believe in DNLI or SANA?

Do analysts rate DNLI or SANA?

Does the media refer more to DNLI or SANA?

Which has more risk & volatility, DNLI or SANA?

Which has higher valuation & earnings, DNLI or SANA?

Is DNLI or SANA more profitable?

Summary

How does Sana Biotechnology compare to Arcus Biosciences?

Which has better valuation & earnings, SANA or RCUS?

Do analysts recommend SANA or RCUS?

Is SANA or RCUS more profitable?

Do insiders and institutionals believe in SANA or RCUS?

Does the media refer more to SANA or RCUS?

Which has more volatility & risk, SANA or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools